We are live on ! Find out more
THNR icon

Amplify Weight Loss Drug & Treatment ETF

6 hedge funds and large institutions have $1.22M invested in Amplify Weight Loss Drug & Treatment ETF in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding

Funds holding: 4 → 6 (+2)

19% more capital inflows, than outflows

Capital inflows: $534K | Capital outflows: $450K

5.73% less ownership

Funds ownership: 26.8% → 21.07% (-5.7%)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

THNR Hedge Fund Activity: Q3 2026 in Review

6 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q3 2026, worth a combined $1.22M — up 4.1% from $1.17M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new THNR positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was GTS Securities, opening a new position worth an estimated $421K. The largest seller was Jane Street, exiting entirely with an estimated $450K sold.

  • 6 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q3 2026, up from 4 in Q2 2026.
  • Funds reported $1.22M of Amplify Weight Loss Drug & Treatment ETF stock for Q3 2026, up 4.1% quarter-over-quarter.
  • 3 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q3 2026 and 1 closed out, a net change of +2 holders.
  • The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q3 2026 was GTS Securities, an estimated $421K added.
  • The largest Amplify Weight Loss Drug & Treatment ETF seller in Q3 2026 was Jane Street, an estimated $450K sold.

Based on aggregated 13F filings for Q3 2026.